GlassScriptPhysician profile
David D Kim
NPI 1174942791
$5,614.13
in general payments reported to CMS, 2019-2025
27 companies · $2,130 in 2025
The $2,130 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $110 · 2021: $202 · 2022: $418 · 2023: $834 · 2024: $1,921 · 2025: $2,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,763 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,762.85 |
| Education | $121.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,309.35 | 2022-2025 | |
| Boston Scientific Corporation | $793.89 | 2021-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Exalt Model D |
| Lilly USA, LLC | $429.32 | 2024-2025 | Omvoh |
| Pfizer INC. | $397.64 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $329.99 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Celltrion USA INC. | $328.40 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Celgene Corporation | $293.03 | 2023-2024 | Zeposia |
| Genzyme Corporation | $284.64 | 2023-2025 | |
| Janssen Biotech, INC. | $217.68 | 2023-2025 | Stelara, Tremfya, Remicade |
| Regeneron Healthcare Solutions, INC. | $166.82 | 2024-2025 | Dupixent |
| Ardelyx, INC. | $151.96 | 2023-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $115.24 | 2022 | |
| Conmed Corporation | $110.10 | 2020 | |
| Madrigal Pharmaceuticals | $107.69 | 2024-2025 | Rezdiffra, Resmetirom |
| Organon LLC | $95.21 | 2022-2025 | Hadlima |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $93.30 | 2024-2025 | Zenpep |
| Gilead Sciences, INC. | $82.78 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $77.89 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $64.87 | 2023 | Dificid |
| Braintree Laboratories, INC. | $49.46 | 2023-2024 | Sutab, Suflave |
| Qol Medical, LLC | $31.73 | 2025 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $18.48 | 2024 | Eohilia |
| Novo Nordisk INC | $17.25 | 2025 | Wegovy |
| Vivus LLC | $16.01 | 2025 | Pancreaze |
| Alnylam Pharmaceuticals INC. | $15.76 | 2022 | |
| Ironwood Pharmaceuticals, INC | $15.64 | 2023 | Linzess |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$26,285.56 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.